Telomerase activity and its inhibition in benign and malignant breast lesions

✍ Scribed by Sugino, Takashi; Yoshida, Kazuhiro; Bolodeoku, John; Tarin, David; Goodison, Steve

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 121 KB
• Volume: 183
• Category: Article
• ISSN: 0022-3417
• DOI: 10.1002/(sici)1096-9896(199709)183:1<57::aid-path1114>3.0.co;2-4

✦ Synopsis

Many types of human tumours and immortal cell lines have been demonstrated to exhibit telomerase activity with the recently formulated telomeric repeat amplification protocol (TRAP assay). However, a small proportion of undoubted tumour samples give a negative result and it has been postulated that, on occasion, the assay can be blocked by inhibitory factors in the cell or tissue extracts. To resolve this issue, a modified TRAP assay has been used to re-examine 45 previously negative breast tissue specimens. Phenol-chloroform extraction of the sample after the telomerase extension reaction revealed the presence of polymerase chain reaction (PCR) inhibitory factors in tissue from 6 of 14 (43 per cent) breast biopsies of fibrocystic disease (FCD), 6 of 12 (50 per cent) fibroadenomas (FAs), none of five carcinomas in situ, and 1 of 13 (8 per cent) invasive carcinoma (CA) tissue specimens. These results demonstrated that the enzyme telomerase can be active in some benign lesions as well as in carcinomas of the breast. Specimens which still remained negative for telomerase in the above experiment were next assayed for the presence of biologically relevant inhibitors of the enzyme by mixing the extracts with confirmed positive samples. Extracts from 12 of 17 carcinoma specimens (all of five carcinomas in situ and 7 of 12 invasive carcinomas showed dose-dependent inhibitory activity against telomere extension, whereas no inhibition was observed in those of three of eight FCD and 2 of seven FAs. These results indicate that telomerase activity may be regulated by a balance between inhibitory factors and an activated enzyme. 1997 by John Wiley & Sons, Ltd.